Evaluating Value of BTK Inhibitors in CLL Treatment

Secondary immunodeficiency disease (SID) status was associated with significantly higher risk for severe bacterial infections in adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

The study offers insights on how to counteract resistance to Bruton tyrosine kinase (BTK) inhibitors.

Long-term data support the safety and efficacy of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL), though questions remain about which patients would benefit most from the regimen.

Meaningful change thresholds for the EORTC Quality of Life Questionnaire in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are: −11/+11 for symptom burden, −16/+16 for physical condition/fatigue, and −16/+13 for worries/fears.

Despite found associations, due to small sample sizes the researchers suggest readers interpret their findings with caution.

This multiyear follow-up of more than 3300 patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who received ibrutinib—the longest study of its kind—confirms the agent’s efficacy as a salvage treatment but reveals new information about its impact in different subpopulations with varying clinical characteristics.